Venetoclax (ven), a pro‐apoptotic Bcl‐2 inhibitor, is an oral agent that can be used in various combinations as the standard of care in patients with acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy [1]. Here, BCL2 is linked to acute myeloid leukemia.